In a sharply divided decision, the FDA's Pharmacy Compounding Advisory Committee voted to add four unapproved peptides—BPC-157, KPV, TB-500, and MOTS-c—to the list of substances compounding pharmacies can legally produce and sell. The committee broke with its own agency scientists, who had concluded the peptides lacked sufficient evidence of safety and efficacy for the conditions they claim to treat, including ulcerative colitis, wound healing, obesity, and osteoporosis.

##...